Pharma BD Deal Intelligence
Sun Pharma's Caraco unit picked up URL Pharma's leftover generics book (Takeda kept the $430M Colcrys flagship) for $60M, absorbing a Philadelphia manufacturing plant into an already-troubled US network. The plant got swept into Sun's 2014-2016 FDA quality crisis and was divested to a CDMO within four years, with no evidence the assets ever generated standalone value.
Sun Pharma announced Caraco's definitive agreement to buy URL Pharma's generics business from Takeda, expanding Sun's US oral-solids footprint.
Sun Pharma's subsidiary Caraco agreed to acquire the non-Colcrys generics business of URL Pharma, enhancing Sun's U.S. portfolio with over 100 products…
Takeda sold its URL Pharma generic business, excluding Colcrys, to Sun Pharma's Caraco unit six months after its $800 million URL acquisition. Financial…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sun Pharma acquired URL Pharma's non-Colcrys generic business from Takeda following Takeda's $800M URL acquisition. Provided Sun with US generics portfolio expansion. Financial terms partially disclosed.
Assessment window: 5yr post-close.
URL Pharma's non-Colcrys business consisted of a broad oral-solids generics portfolio across multiple therapeutic categories, sold under the Mutual Pharmaceutical, URL, and AR Scientific banners. After Takeda paid $800M for URL primarily to acquire Colcrys (single-ingredient oral colchicine for gout), the residual generics business was sold to Sun Pharma's Caraco subsidiary.
The 2012 US generics market was led by Teva, Mylan, Sandoz (Novartis), Watson/Actavis, Hospira, and Dr Reddy's, with Sun Pharma steadily climbing the rankings via tuck-in acquisitions of Caraco (controlling stake), Taro Pharmaceutical, and Dusa. Avendus Capital analyst Monica Joshi noted URL's '280+ ANDAs with minimal overlap' to Sun's existing portfolio could 'accelerate portfolio growth and improve profitability'. ICICI Direct analysts highlighted Sun's 'uncanny knack of acquiring unique players to bolster its US portfolio.' The deal mattered for two reasons: (1) Sun extracted a high-ANDA-count generics tail at a fraction of Takeda's $800M URL price after Takeda monetized Colcrys separately — Colcrys generated $155M in net sales in just June-Sep 2012; and (2) it accelerated Sun's US footprint amid the 2011-2012 patent cliff (Lipitor, Plavix, Singulair losing exclusivity), where ANDA-dense portfolios commanded premium strategic value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) (this deal) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. | 2025 | $355M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2012 deals · Sun Pharmaceutical Industries Ltd. deals · Other deals